These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 3100576)
1. Bone marrow transplantation in canine mucopolysaccharidosis I. Effects within the central nervous system. Shull RM; Hastings NE; Selcer RR; Jones JB; Smith JR; Cullen WC; Constantopoulos G J Clin Invest; 1987 Feb; 79(2):435-43. PubMed ID: 3100576 [TBL] [Abstract][Full Text] [Related]
2. Intracerebroventricular transplantation of human bone marrow-derived multipotent progenitor cells in an immunodeficient mouse model of mucopolysaccharidosis type I (MPS-I). Nan Z; Shekels L; Ryabinin O; Evavold C; Nelson MS; Khan SA; Deans RJ; Mays RW; Low WC; Gupta P Cell Transplant; 2012; 21(7):1577-93. PubMed ID: 22472595 [TBL] [Abstract][Full Text] [Related]
3. Long-term neurological effects of bone marrow transplantation in a canine lysosomal storage disease. Shull RM; Breider MA; Constantopoulos GC Pediatr Res; 1988 Sep; 24(3):347-52. PubMed ID: 3145485 [TBL] [Abstract][Full Text] [Related]
4. Bone marrow transplantation for feline mucopolysaccharidosis I. Ellinwood NM; Colle MA; Weil MA; Casal ML; Vite CH; Wiemelt S; Hasson CW; O'Malley TM; He X; Prociuk U; Verot L; Melniczek JR; Lannon A; Aguirre GD; Knox VW; Evans SM; Vanier MT; Schuchman EH; Walkley SU; Haskins ME Mol Genet Metab; 2007 Jul; 91(3):239-50. PubMed ID: 17482862 [TBL] [Abstract][Full Text] [Related]
5. Long-term effects of bone marrow transplantation in dogs with mucopolysaccharidosis I. Breider MA; Shull RM; Constantopoulos G Am J Pathol; 1989 Mar; 134(3):677-92. PubMed ID: 2493739 [TBL] [Abstract][Full Text] [Related]
6. Morphologic and biochemical studies of canine mucopolysaccharidosis I. Shull RM; Helman RG; Spellacy E; Constantopoulos G; Munger RJ; Neufeld EF Am J Pathol; 1984 Mar; 114(3):487-95. PubMed ID: 6320652 [TBL] [Abstract][Full Text] [Related]
7. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431 [TBL] [Abstract][Full Text] [Related]
8. Mucopolysaccharidosis type V. (Scheie syndrome). A postmortem study by multidisciplinary techniques with emphasis on the brain. Dekaban AS; Constantopoulos G; Herman MM; Steusing JK Arch Pathol Lab Med; 1976 May; 100(5):237-45. PubMed ID: 817693 [TBL] [Abstract][Full Text] [Related]
9. Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow. Zheng Y; Rozengurt N; Ryazantsev S; Kohn DB; Satake N; Neufeld EF Mol Genet Metab; 2003 Aug; 79(4):233-44. PubMed ID: 12948739 [TBL] [Abstract][Full Text] [Related]
10. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Keeling KM; Brooks DA; Hopwood JJ; Li P; Thompson JN; Bedwell DM Hum Mol Genet; 2001 Feb; 10(3):291-9. PubMed ID: 11159948 [TBL] [Abstract][Full Text] [Related]
11. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Kakkis ED; McEntee MF; Schmidtchen A; Neufeld EF; Ward DA; Gompf RE; Kania S; Bedolla C; Chien SL; Shull RM Biochem Mol Med; 1996 Aug; 58(2):156-67. PubMed ID: 8812735 [TBL] [Abstract][Full Text] [Related]
12. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Dickson P; McEntee M; Vogler C; Le S; Levy B; Peinovich M; Hanson S; Passage M; Kakkis E Mol Genet Metab; 2007 May; 91(1):61-8. PubMed ID: 17321776 [TBL] [Abstract][Full Text] [Related]
13. Corneal opacity in canine MPS I. Changes after bone marrow transplantation. Constantopoulos G; Scott JA; Shull RM Invest Ophthalmol Vis Sci; 1989 Aug; 30(8):1802-7. PubMed ID: 2503461 [TBL] [Abstract][Full Text] [Related]
14. Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice. Chung S; Ma X; Liu Y; Lee D; Tittiger M; Ponder KP Mol Genet Metab; 2007 Feb; 90(2):181-92. PubMed ID: 16979922 [TBL] [Abstract][Full Text] [Related]
16. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. Dickson P; Peinovich M; McEntee M; Lester T; Le S; Krieger A; Manuel H; Jabagat C; Passage M; Kakkis ED J Clin Invest; 2008 Aug; 118(8):2868-76. PubMed ID: 18654665 [TBL] [Abstract][Full Text] [Related]
18. Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice. Watson G; Bastacky J; Belichenko P; Buddhikot M; Jungles S; Vellard M; Mobley WC; Kakkis E Gene Ther; 2006 Jun; 13(11):917-25. PubMed ID: 16482204 [TBL] [Abstract][Full Text] [Related]
19. Neonatal bone marrow transplantation prevents bone pathology in a mouse model of mucopolysaccharidosis type I. Pievani A; Azario I; Antolini L; Shimada T; Patel P; Remoli C; Rambaldi B; Valsecchi MG; Riminucci M; Biondi A; Tomatsu S; Serafini M Blood; 2015 Mar; 125(10):1662-71. PubMed ID: 25298037 [TBL] [Abstract][Full Text] [Related]
20. [Alpha-L-iduronidase activity in fibroblasts of patients with Hurler syndrome]. Stareprawo G; Grimm U; Machill G; Knapp A; Wehnert M Acta Biol Med Ger; 1975; 34(6):1079-82. PubMed ID: 812313 [No Abstract] [Full Text] [Related] [Next] [New Search]